Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Daniela Smaniotto
Based on 1 article published since 2010
(Why 1 article?)
||||

Between 2010 and 2020, Daniela Smaniotto wrote the following article about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Clinical Trial Long-term analysis of gemcitabine-based chemoradiation after surgical resection for pancreatic adenocarcinoma. 2013

Mattiucci, Gian Carlo / Ippolito, Edy / D'Agostino, Giuseppe Roberto / Alfieri, Sergio / Antinori, Armando / Crucitti, Antonio / Balducci, Mario / Deodato, Francesco / Luzi, Stefano / Macchia, Gabriella / Smaniotto, Daniela / Morganti, Alessio Giuseppe / Valentini, Vincenzo. ·Department of Radiotherapy, Policlinico Universitario "Agostino Gemelli", Catholic University, Rome, Italy. ·Ann Surg Oncol · Pubmed #23208130.

ABSTRACT: PURPOSE: To evaluate the efficacy in terms of local control (LC) of 24 h infusion of gemcitabine plus radiotherapy after surgery for pancreatic cancer. METHODS: Weekly gemcitabine (100 mg/m(2)) was provided as a 24-hour infusion during the course of radiotherapy (50.4 Gy to the tumor, 39.6 Gy to the nodes). Patients subsequently received five cycles of gemcitabine monochemotherapy (1,000 mg/m(2) 1, 8, q21). The primary end point of the study was to achieve a 2-year LC rate of ≥80 % with type I and II errors of 5 and 20 %. The study was designed to accrue a maximum sample size of 35 patients. Secondary end points were toxicity evaluation, metastasis-free survival (MFS), and overall survival (OS). RESULTS: Data of 35 patients were available. Most of the patients (n = 27; 77.1 %) had duodeno-cephalo-pancreatectomy, 5 (14.3 %) distal pancreatectomy, and 3 (8.6 %) total pancreatectomy. The pathological stages were T1-T2 (n = 7; 20.0 %), T3-T4 (n = 28; 80.0 %), N0 (n = 17; 48.6 %), and N1 (n = 18; 51.4 %). Thirty patients (85.7 %) completed chemoradiation. Twenty-three patients (65.7 %) received further sequential chemotherapy. Acute toxicity was acceptable. No late toxicity occurred. The median follow-up period was 64 (range 24-118) months, and 2-year crude rate of LC was 83 (median not reached). Median MFS and OS were 26.5 and 22.5 months, respectively. CONCLUSIONS: The rate of LC met the main goal of the study. The regimen resulted in a high LC rate but failed to show a benefit in terms of OS or MFS, thus suggesting the need for a more intensified multimodal approach.